Loading
Immunocore Holdings plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BAKER BROS. ADVISORS LP, was filed 19 Mar 2025.
Insider Decl.
54
Thresholds
n/a
Buy Volume
€22M
4 ops. · all time
Sell Volume
€17M
30 ops. · all time
Who traded when
BuySaleDavid M. Berman14 sales
Baker Bros. Advisors LP4 buys
Bahija Jallal1 sale
John Goll1 sale
Tina Amber St Leger1 sale
Since the insiders bought
- -1.7%Entry US$30.43 · Close at T+365 US$29.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,797 of 26,246 companies
37.0
score / 100
Value29
Quality45
FCF yld-1.0%
Earn yld-2.3%
EV/EBITDA·
ROE-4.5%
Gross mgn99%
Net mgn-8.9%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$29.86
Analyst consensus
11 analysts1.77/5
US$34.00Target US$62.73(+110%)US$100.00
Income statement
RevenueUS$400M
Gross profitUS$394.9M99% margin
EBITDA-US$3.7M-1% margin
Net income-US$35.5M-4.2% margin
Valuation
PER (forward)-39.6x
P/Book3.7x
Beta0.82
Balance sheet & cash
Market capUS$1.5B
Total debtUS$436.7M
Free Cash Flow-US$15.1M
Debt / Equity104%
Profitability & ownership
ROE-4.5%
ROA-0.2%
% insiders0.1%
% institutions103.2%
Last declaration on 19 February 2026
Declarations54 total
1,000 shares@ US$32.353.4% of flowOrdinary SharesSEC:0001969525-26-000002:1
11,474 shares@ US$32.35100.0% of flowOrdinary SharesSEC:0001730038-26-000002:1
5,965 shares@ US$32.350.7% of flowOrdinary SharesSEC:0001955244-26-000002:1
698 shares@ US$32.35100.0% of flowOrdinary SharesSEC:0001779466-26-000002:1
1,351 shares0Ordinary SharesSEC:0001779466-26-000002:0
23,817 shares0Ordinary SharesSEC:0001730038-26-000002:0
2,119 shares0Ordinary SharesSEC:0001969525-26-000002:0
11,824 shares0Ordinary SharesSEC:0001955244-26-000002:0
31,341 shares@ US$40.264.9% of flowOrdinary SharesSEC:0001955244-25-000015:1
572 shares@ US$17.460.0% of flowOrdinary SharesSEC:0001955244-25-000015:2
572 shares@ US$40.140.1% of flowOrdinary SharesSEC:0001955244-25-000015:3
31,341 shares@ US$17.469.4% of flowOrdinary SharesSEC:0001955244-25-000015:0
69,404 shares@ US$40.1210.9% of flowOrdinary SharesSEC:0001955244-25-000013:1
5,521 shares@ US$17.460.4% of flowOrdinary SharesSEC:0001955244-25-000013:2
5,521 shares@ US$40.090.9% of flowOrdinary SharesSEC:0001955244-25-000013:3
69,404 shares@ US$17.4621.0% of flowOrdinary SharesSEC:0001955244-25-000013:0
100 shares@ US$40.000.0% of flowOrdinary SharesSEC:0001955244-25-000011:1
18,020 shares@ US$17.461.2% of flowOrdinary SharesSEC:0001955244-25-000011:2
18,020 shares@ US$40.032.8% of flowOrdinary SharesSEC:0001955244-25-000011:3
100 shares@ US$17.460.0% of flowOrdinary SharesSEC:0001955244-25-000011:0
61,849 shares@ US$35.238.4% of flowOrdinary SharesSEC:0001955244-25-000008:1
61,849 shares@ US$17.4618.5% of flowOrdinary SharesSEC:0001955244-25-000008:0
22,532 shares@ US$17.466.7% of flowOrdinary SharesSEC:0001955244-25-000005:0
21,232 shares@ US$35.6312.9% of flowOrdinary SharesSEC:0001955244-25-000005:1
1,300 shares@ US$36.310.8% of flowOrdinary SharesSEC:0001955244-25-000005:2
25 of 54 declarations
About Immunocore Holdings plc
On March 17, 2025, Baker Bros. Advisors LP, filed as Director, bought EUR 17,664,932, EUR 2,508,772 and EUR 1,642,976 at Immunocore Holdings plc, which are the record's 4 purchases: EUR 22.1 million in all, with a median of EUR 2,075,874, and 12% of open-market trades. Baker Bros. Advisors LP signs 4 filings, all purchases.
The 30 sales total EUR 17.3 million (median EUR 272,854). David M. Berman, HEAD OF R&D, signs the three largest: EUR 2,407,719 on November 26, 2025, EUR 1,856,653 on September 30, 2025 and EUR 1,730,149 on February 26, 2024. Berman is also the most frequent filer, with 39 of the 54 filings, 24 of them sales. Tina Amber St Leger (CHIEF HR OFFICER) signs 7, 4 of them sales; Bahija Jallal (CHIEF EXECUTIVE OFFICER) and John Goll (SVP, FINANCE & CAO) 2 each, with 1 sale each.
Read moreShow less
The record runs from January 5, 2024 to February 19, 2026: 18 filings in 2024, 28 in 2025 and 8 in 2026, with 20 option exercises. The US health care company, valued at USD 1.54 billion, has only 5 filers, who hold 0.1% of the capital. Over the last twelve months: 20 filings, 10 of them sales and no purchase. The median publication delay is 2 days.
